Affiliation:
1. First Hospital of Shanxi Medical University
2. Shanxi Medical University
Abstract
Abstract
Background
Hepatocellular carcinoma (HCC) is a malignant tumor of the liver. Aerobic glycolysis is the reason for the high proliferation rate of HCC cells. In addition, PI3K / Akt pathway stimulates angiogenesis, which is beneficial to the growth of HCC cells. The aim of this research was to screen biomarkers related to glycolysis and PI3K/Akt signaling pathway in HCC.
Methods
In TCGA-LIHC dataset, differential analysis was performed to screen out the DEGs between tumor and normal groups. The candidate genes were obtained through overlapping DEGs, GMRGs and PI3K/Akt signaling pathway-related genes. Biomarkers were identified by ten algorithms in the PPI network. The correlation between angiogenesis/autophagy/apoptosis/EMT and biomarkers was analyzed.
Results
A sum of 7476 DEGs were obtained between tumor and normal groups. Soon afterwards, 20 candidate genes were obtained. Then, we identified 4 biomarkers (ANGPT2, FLT3, IGF1 and SPP1) via PPI. we found these biomarkers were positively associated with angiogenesisa, autophagy, apoptosis and EMT. Finally, ANGPT2 and SPP1 was higher expressed in HCC group compared to the normal group.
Conclusion
Overall, we obtained four biomarkers related to glycolysis and PI3K/Akt signaling pathway (ANGPT2, FLT3, IGF1 and SPP1) associated with HCC, which laid a theoretical foundation for the treatment of HCC.
Publisher
Research Square Platform LLC
Reference46 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global Cancer S. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
2. Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression;Bai Y;J Cell Physiol,2019
3. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616. 10.1038/s41571-018-0073-4. PMID: 30061739.
4. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008;7(1):110 – 20. 10.1158/1535-7163.MCT-07-0482. PMID: 18202014.
5. Ros S, Schulze A. Glycolysis back in the limelight: systemic targeting of HK2 blocks tumor growth. Cancer Discov. 2013;3(10):1105-7. 10.1158/2159-8290.CD-13-0565. PMID: 24124231.